Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rituximab: applications in dermatology.

Mitra M Fatourechi1, Rokea A el-Azhary, Lawrence E Gibson

  • 1University of Minnesota Medical School, Minneapolis, USA.

International Journal of Dermatology
|October 17, 2006
PubMed
Summary

Rituximab, an anti-CD20 antibody, shows promise for autoimmune skin diseases beyond B-cell cancers. Further clinical trials are needed to confirm its efficacy in these dermatologic conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Panniculitis: a narrative review.

Archives of dermatological research·2025
Same author

Primary cutaneous melanoma of the breast skin: Incidence, characteristics, and management.

JAAD international·2024
Same author

Incidence and mortality trends of primary cutaneous melanoma: A 50-year Rochester Epidemiologic Project study.

JAAD international·2024
Same author

Association of Lower Extremity Lymphedema and Nonmelanoma Skin Cancers.

Mayo Clinic proceedings·2023
Same author

Increasing Incidence and Decreasing Mortality of Melanoma in Elderly Adults: An Epidemiologic Study in Olmsted County, Minnesota.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]·2023
Same author

The incidence of periocular melanoma: An epidemiologic study in Olmsted County, Minnesota.

JAAD international·2023

Area of Science:

  • Immunology
  • Dermatology
  • Oncology

Background:

  • Rituximab is a chimeric anti-CD20 monoclonal antibody.
  • It is widely used for B-lymphocytic malignancies.
  • Emerging applications include autoimmune diseases.

Purpose of the Study:

  • To review the current applications of rituximab in dermatologic conditions.
  • To highlight its potential in autoimmune and malignant skin diseases.
  • To identify the need for further clinical investigation.

Main Methods:

  • Review of existing case reports and literature.
  • Analysis of rituximab's mechanism of action in B-cell depletion.
  • Identification of specific dermatologic conditions treated with rituximab.

Main Results:

  • Case reports suggest rituximab efficacy in paraneoplastic pemphigus, pemphigus vulgaris, graft versus host disease, and cutaneous B-cell malignancies.
  • Rituximab targets CD20-expressing B-cells, relevant in both hematologic malignancies and certain autoimmune conditions.
  • Evidence is primarily based on case studies, lacking large-scale clinical trials.

Conclusions:

  • Rituximab demonstrates potential therapeutic value in various dermatologic conditions.
  • Its use in autoimmune blistering diseases and cutaneous B-cell lymphomas is supported by preliminary evidence.
  • Controlled clinical trials are essential to establish definitive efficacy and safety profiles.

Related Experiment Videos